Valproic acid suppresses interleukin-1β-induced microsomal prostaglandin E 2 synthase-1 expression in chondrocytes through upregulation of NAB1

Journal of Rheumatology

Volumn 38, Issue 3, 2011, Pages 492-502

  Zayed, Nadia ^a   El Mansouri, Fatima Ezzahra ^a   Chabane, Nadir ^a   Kapoor, Mohit ^a   Martel Pelletier, Johanne ^a   Benderdour, Mohamed ^b   Pelletier, Jean Pierre ^a   Duval, Nicolas ^c   Fahmi, Hassan ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c Duval Orthopaedic Clinic   (Canada)

Author keywords

Chondrocytes; Microsomal prostaglandin E synthase 1; NGF1 A binding protein 1; Valproic acid

Indexed keywords

BINDING PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; MESSENGER RNA; MICROSOMAL PROSTAGLANDIN E2 SYNTHASE 1; NGF1 A BINDING PROTEIN 1; PROSTAGLANDIN E SYNTHASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VALPROIC ACID;

AGED; ARTICLE; CARTILAGE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; UPREGULATION;

CHONDROCYTES; EARLY GROWTH RESPONSE PROTEIN 1; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-1BETA; INTRAMOLECULAR OXIDOREDUCTASES; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; VALPROIC ACID;

EID: 79952394907     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100907     Document Type: Article

References (52)

1. Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ, Rediske J, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest 1997;99:1231-7. (Pubitemid 27142759)
2. Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002;46:1789-803. (Pubitemid 34774511)
3. Mehindate K, al-Daccak R, Dayer JM, Kennedy BP, Kris C, Borgeat P, et al. Superantigen-induced collagenase gene expression in human IFN-gamma-treated fibroblast-like synoviocytes involves prostaglandin E2. Evidence for a role of cyclooxygenase-2 and cytosolic phospholipase A2. J Immunol 1995;155:3570-7.
4. Miwa M, Saura R, Hirata S, Hayashi Y, Mizuno K, Itoh H. Induction of apoptosis in bovine articular chondrocyte by prostaglandin E(2) through cAMP-dependent pathway. Osteoarthritis Cartilage 2000;8:17-24.
5. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 2003;33:155-67. (Pubitemid 38030079)
6. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001;107:1491-5. (Pubitemid 32574631)
7. Fahmi H. mPGES-1 as a novel target for arthritis. Curr Opin Rheumatol 2004;16:623-7.
8. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000;275:32775-82.
9. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000;275:32783-92.
10. Murakami M, Nakashima K, Kamei D, Masuda S, Ishikawa Y, Ishii T, et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003;278:37937-47. (Pubitemid 37175324)
11. Li X, Afif H, Cheng S, Martel-Pelletier J, Pelletier JP, Ranger P, et al. Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes. J Rheumatol 2005;32:887-95. (Pubitemid 40676500)
12. Kojima F, Naraba H, Miyamoto S, Beppu M, Aoki H, Kawai S. Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis. Arthritis Res Ther 2004;6:R355-65.
13. Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, Klareskog L, et al. Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum 2004;50:1774-80.
14. Claveau D, Sirinyan M, Guay J, Gordon R, Chan CC, Bureau Y, et al. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol 2003;170:4738-44. (Pubitemid 36519982)
15. Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M, Nakatani Y, Oh-Ishi S, et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. J Biol Chem 2004;279:33684-95. (Pubitemid 39063018)
16. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 2003;100:9044-9. (Pubitemid 36899220)
17. Stichtenoth DO, Thoren S, Bian H, Peters-Golden M, Jakobsson PJ, Crofford LJ. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 2001;167:469-74. (Pubitemid 32567813)
18. Naraba H, Yokoyama C, Tago N, Murakami M, Kudo I, Fueki M, et al. Transcriptional regulation of the membrane-associated prostaglandin E2 synthase gene. Essential role of the transcription factor Egr-1. J Biol Chem 2002;277:28601-8. (Pubitemid 41079288)
19. Cheng S, Afif H, Martel-Pelletier J, Pelletier JP, Li X, Farrajota K, et al. Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1 beta-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J Biol Chem 2004;279:22057-65. (Pubitemid 38679397)
20. Russo MW, Sevetson BR, Milbrandt J. Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription. Proc Natl Acad Sci USA 1995;92:6873-7.
21. Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol 1996;16:3545-53. (Pubitemid 26199873)
22. Urnov FD. Chromatin remodeling as a guide to transcriptional regulatory networks in mammals. J Cell Biochem 2003;88:684-94. (Pubitemid 36258818)
23. Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 2007;14:1008-16. (Pubitemid 350060343)
24. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000;60:4561-72. (Pubitemid 32103641)
25. Chang S, Pikaard CS. Transcript profiling in Arabidopsis reveals complex responses to global inhibition of DNA methylation and histone deacetylation. J Biol Chem 2005;280:796-804. (Pubitemid 40165048)
26. Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 2005;24:4894-907. (Pubitemid 41129094)
27. Nawaz Z, Baniahmad C, Burris TP, Stillman DJ, O'Malley BW, Tsai MJ. The yeast SIN3 gene product negatively regulates the activity of the human progesterone receptor and positively regulates the activities of GAL4 and the HAP1 activator. Mol Gen Genet 1994;245:724-33.
28. Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA 2000;97:13708-13.
29. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005;11:1-15.
30. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, et al. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res 2005;134:162-9. (Pubitemid 40403648)
31. Chen PS, Wang CC, Bortner CD, Peng GS, Wu X, Pang H, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007;149:203-12. (Pubitemid 47488650)
32. Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ, et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007;122:596-606. (Pubitemid 350075958)
33. Chabane N, Zayed N, Afif H, Mfuna-Endam L, Benderdour M, Boileau C, et al. Histone deacetylase inhibitors suppress interleukin-1 beta-induced nitric oxide and prostaglandin E(2) production in human chondrocytes. Osteoarthritis Cartilage 2008;16:1267-74.
34. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002;99:2995-3000. (Pubitemid 34240574)
35. Young DA, Lakey RL, Pennington CJ, Jones D, Kevorkian L, Edwards DR, et al. Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 2005;7:R503-12.
36. Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D, Sanders ME, et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 2010;184:2718-28.
37. Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 2004;83 Suppl 1:S91-2.
38. Altman RD. Criteria for the classification of osteoarthritis of the knee and hip. Scand J Rheumatol Suppl 1987;65:31-9. (Pubitemid 17165512)
39. Farrajota K, Cheng S, Martel-Pelletier J, Afif H, Pelletier JP, Li X, et al. Inhibition of interleukin-1 beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-delta 12, 14-prostaglandin J2 through a histone deacetylase-independent mechanism. Arthritis Rheum 2005;52:94-104. (Pubitemid 40129237)
40. Chabane N, Li X, Fahmi H. HDAC4 contributes to IL-1-induced mPGES-1 expression in human synovial fibroblasts through up-regulation of Egr-1 transcriptional activity. J Cell Biochem 2009;106:453-63.
41. Swirnoff AH, Apel ED, Svaren J, Sevetson BR, Zimonjic DB, Popescu NC, et al. Nab1, a corepressor of NGFI-A (Egr-1), contains an active transcriptional repression domain. Mol Cell Biol 1998;18:512-24. (Pubitemid 28021062)
42. Thiel G, Kaufmann K, Magin A, Lietz M, Bach K, Cramer M. The human transcriptional repressor protein NAB1: expression and biological activity. Biochim Biophys Acta 2000;1493:289-301.
43. Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21 (WAF1/Cip1) expression. Arthritis Rheum 2004;50:3365-76. (Pubitemid 39372015)
44. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007;150:862-72. (Pubitemid 46536628)
45. Nasu Y, Nishida K, Miyazawa S, Komiyama T, Kadota Y, Abe N, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 2008;16:723-32.
46. Fan W, Ma JX, Cheng L, Norris JS. Molecular cloning of TA16, a transcriptional repressor that may mediate glucocorticoid-induced growth arrest of leiomyosarcoma cells. Mol Endocrinol 1997;11:1342-52. (Pubitemid 28041340)
47. Qiu FH, Devchand PR, Wada K, Serhan CN. Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils. FASEB J 2001;15:2736-8.
48. Marinova Z, Ren M, Wendland JR, Leng Y, Liang MH, Yasuda S, et al. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 2009;111:976-87.
49. Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009;28:3097-110.
50. Gul H, Marquez-Curtis LA, Jahroudi N, Larratt LM, Janowska-Wieczorek A. Valproic acid exerts differential effects on CXCR4 expression in leukemic cells. Leuk Res 2010;34:235-42.
51. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005;363:15-23. (Pubitemid 41691888)
52. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009;41:185-98.